Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Matthay

Showing results (301-310 of 316) with videos related to

Pageof 32
Sort By:
Pediatric Blood & Cancer|April 1, 2018
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialNavin Pinto, Steven G DuBois, Araz Marachelian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 3, 2015
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II studyGregory A Yanik, Judith G Villablanca, John M Maris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2017
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and PrognosisAraz Marachelian, Judith G Villablanca, Cathy W Liu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2017
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trialsRuth Ladenstein, Bieke Lambert, Ulrike Pötschger, et al.
The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology GroupAmi V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Susan Groshen, Julie R Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology GroupAmy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Pageof 32

Showing results (301-310 of 316) with videos related to

Sort By:
Pageof 32
Pediatric Blood & Cancer|April 1, 2018
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialNavin Pinto, Steven G DuBois, Araz Marachelian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 3, 2015
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II studyGregory A Yanik, Judith G Villablanca, John M Maris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2017
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and PrognosisAraz Marachelian, Judith G Villablanca, Cathy W Liu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2017
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trialsRuth Ladenstein, Bieke Lambert, Ulrike Pötschger, et al.
The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology GroupAmi V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Susan Groshen, Julie R Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology GroupAmy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Pageof 32